The Motley Fool··Prosper Junior BakinyPfizer vs. Moderna: Navigating Pharma's Post-Pandemic Pivot
Moderna's 69% YTD gain reflects mRNA vaccine upside, while Pfizer's 6.3% dividend offers stability as COVID revenues fade. Choice depends on risk appetite.
MRKPFEMRNAbiotechclinical trials